A part of the reason that large doses are administered is that almost every article written on this topic avers that the administration of small doses is "controversial". Now, moreover, we read that the high dose is, indeed, "superior". At least in the title of the article. Were we wrong? Have we been misled in our thinking by the vagaries of metaanalysis, in which comparisons are, of necessity, made between groups that may not be strictly comparable? In the current issue of Blood we now have a study that uses a more robust approach, the retrospective matching of patients. In fact, it is perhaps the best study to date in which high dose and low dose therapy have been compared in matched cases. And we read in the title, at least that "superior" results are achieved with high doses. But read on. At least the abstract.
Here is a direct quote: "Improvement in hemoglobin, platelet count and hepatosplenomegaly was not significantly different between both cohorts, whereas
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From plasma chitotriosidase and bone marrow involvement by MRI improved faster and more pronounced in the high dose group. Major bone complications rarely occurred in both groups." Although high dose enzyme therapy did have a superior effect on two surrogates of the disease it had none on the actual disease manifestations of the patients.
Thus, while the title implies that the high doses of enzyme replacement for Gaucher disease are, after all, superior to the low doses that we have recommended, the conclusions that the authors draw in the paper itself are quite the opposite: Low dose therapy has the same effect as high dose therapy on all of the important clinical manifestations of the disease. The blood hemoglobin concentration, platelet count, regression of spleen and liver and the frequency of bone crises are the same.
"Superiority" of the high dose, costing about $400,000 per year more for a 70 Kg patient, is limited to the response of two surrogate markers, serum chitotriosidase and MRI scanning of the marrow.
So let us look a little further at the surrogates, and what they tell us. The fact that chitotriosidase levels decrease more rapidly with high dose therapy than with low dose therapy has been found in two other less well controlled studies 4, 5 , and the confirmation of this finding is welcome. The finding that marrow fat increases more rapidly with high dose treatment is, as far as we know, a unique finding. But for the clinician the important question is "Do these parameters measure disease severity in a meaningful way"? While the authors suggest that they may, our experience and the published literature suggest otherwise. happens, and a number of studies have shown that marrow fat, as measured by MRI, increases with enzyme replacement therapy. The questions that has not been adequately addressed before is whether the rate of disappearance is proportional to the enzyme dose given. In an earlier study from the Dutch group 9 there seemed to be no difference, but in the current larger comparative study, the return of fat to the marrow was considerably more rapid at high enzyme doses.
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Again, we must ask, does it matter? Because the marrow resides within the skeleton, changes in bone marrow MRI are sometimes uncritically regarded as surrogates of skeletal disease. While there may be a relationship between marrow and skeletal lesions because of the intimate contact between them, this is by no means necessarily true.
Indeed, in the present study both hematologic recovery (representing marrow function) and clinical bone disease were dose independent. Do the MRI measurements have any relationship to bone disease at all? The authors state: "Fat fraction measurements of the lumbar spine… shows a close correlation of the appearance of clinical complications," citing one of their earlier studies 10 , but as shown in figure 1 taken from that publication, there is, in fact, scarcely any relationship at all.
So the conclusions to be drawn from this excellent clinical study are clear. More is not better. The fact that high dose enzyme replacement therapy is "superior" when two surrogates of disease activity are measured should not influence our choice of treatment regimens. Would we prescribe an anti-leukemic drug really because it lowered the white count if it failed to decrease morbidity or increase lifespan? Of course not. Would we prescribe an anti-cholesterol drug that lowered the blood cholesterol level it had no effect on the incidence of heart attack, stroke, or lifespan? We wouldn't do that either. Then why would we prescribe a very expensive treatment schedule that affected the Sierra marker and an MRI measurement that had no effect on the clinical course? As physicians, our concern must be the regression of organomegaly, development of clinically meaningful bone disease, and the correction of anemia in thrombocytopenia, when it exists. What De Fost et al. have shown once again is that these important aims can be
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